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Abstract 
Despite the prevalence of prostate cancer its pathogenesis remains unclear. Marked 
differences in mortality rates have been observed between countries, however, it is 
unclear whether the source of the observed differences is driven by underlying genetics, 
geographic, or social factors. This thesis investigated the impact of ethnicity and 
immigration on prostate cancer mortality in Canada using the Canadian Census Health 
and Environment Cohort. South Asian and East Asian men were seen to be at decreased 
risk of prostate cancer mortality, while no increased risk was observed in black men. 
These results affirm studies showing lower risks in Asian men; however, they contradict 
the previously held notion that black men are at increased risk of aggressive disease. 
Attempts to study the impact of immigration on prostate cancer mortality were limited 
by small sample sizes and missing data. Efforts to improve linkages and a longer 
timespan may allow for future analysis.  
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Summary for lay audience 
Prostate cancer is one of the most commonly diagnosed and most deadly male cancers. 
Despite its prevalence, surprisingly little is known about what causes prostate cancer 
and who is at an increased risk. This study used a Statistics Canada dataset with detailed 
demographic and health data to track a cohort of the Canadian population over an 18-
year period to determine the impact of ethnicity and immigration on the risk of dying 
from prostate cancer. In our cohort, Asian-Canadians had lower rates of prostate cancer 
mortality, while Black-Canadians had equivalent mortality rates to non-visible minority 
Canadians. This is contradictory to previous studies that showed increased rates of early 
and aggressive prostate cancer in African Americans. Our study looking at the impact of 
immigration on prostate cancer mortality showed the dataset to be currently too 
immature to contribute meaningful data, however this may improve with time. 
Our studies demonstrate the importance of considering confounding variables – most 
importantly socioeconomic factors and access to care when interpreting studies from 
large datasets. Additionally, they identified potential future avenues of research, 
specifically trying to understand the underlying cause of the improved mortality rates in 
Asian Canadians and working to strengthen the dataset to allow more detailed analysis.  
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Preamble and Outline 
The incidence and mortality of prostate cancer varies markedly across the world. While 
certain regions are known to have increased rates, defining the true etiology and 
epidemiology of a cancer among different populations is a constant moving target. It 
may not be immediately apparent whether an observed difference is due to an inherent 
genetic predisposition for the disease, exposure to environmental, social, or cultural risk 
factors, or due to reduced access to healthcare – or a combination of them all. 
Population-level datasets and immigration studies provide the opportunity to evaluate 
the impact of genetic and environmental factors on cancer risks. Observing changes in 
cancer risks among ethnic and immigrant populations compared to their home or host 
country allows one to observe the interplay between genetics, the environment, and 
cancer risks. These studies have the potential to identify novel avenues for improving 
our understanding of cancer genomics, detection, and treatment. Canada is uniquely 
situated to answer this question due to its universal healthcare model and diverse 
population. 
This thesis is a multidisciplinary project performed in conjunction with the Department 
of Surgery at London Health Sciences Centre and the Department of Sociology and 
Statistics at Western University. The primary aim is to investigate the impact of ethnicity 
and immigration on prostate cancer mortality in Canada using Statistics Canada’s 
Canadian Census Health and Environment Cohorts (CanCHEC) database.  
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The thesis is organized in an integrated article format. Chapter 1 introduces the 
fundamentals of prostate cancer, immigration studies, and the CanCHEC database and 
provides a literature review of the current understanding of the link between ethnicity, 
immigration, and prostate cancer. Chapter 2 presents the aims and hypotheses of 
chapters 3 and 4, two self contained manuscripts using the CanCHEC to investigate the 
impacts of ethnicity (chapter 3) and immigration (chapter 4) on prostate cancer 
mortality in Canadian men. Chapters 5 and 6 provide a general discussion, future 
directions and conclusions on the research questions discussed in earlier chapters. 
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CHAPTER 1:  
Introduction and Literature Review 
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Prostate Cancer 
Prostate cancer is the most common non-cutaneous cancer in Canadian men. 1 in 9 
Canadian men will be diagnosed over their lifetime and 1 in 29 will die from prostate 
cancer.1 While no contemporary series exists examining the economic impact of 
prostate cancer in Canada, a study from 2000 estimated the impact of prostate cancer in 
5.8 million Canadian men at $4-8 billion over their lifetime. Given the advances in 
screening, monitoring, and treatment these numbers are expected to have risen 
substantially.2  
Diagnosis and staging 
In the current Canadian landscape, prostate cancers are most often detected after an 
elevated prostate specific antigen (PSA) or suspicious digital rectal examination prompts 
referral to a urologist.3(p1) If the patient is found to be high risk after assessment a 
prostate biopsy is performed for histologic diagnosis. While nuances and controversies 
exist regarding the role of early detection of prostate cancer screening and treatment, 
their discussion is beyond the scope of this thesis. The purpose of this section is to 
provide the reader with a brief understanding of the standard approach often applied by 
urologists in western nations, as recommended by societal guidelines. 
Prostate Specific Antigen 
Prostate specific antigen is a serine protease produced nearly exclusively by prostatic 
luminal epithelial cells that functions to liquify semen and aids in insemination. PSA 
elevation is thought to occur through disruption of cellular basement membrane and 
subsequent leakage of PSA into the serum and may be caused by both benign and 
malignant insults.4 The sensitivity and specificity of a PSA >4 ng/mL has is 0.90% and 
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0.72% respectively. Several approaches have been described attempting to improve the 
performance of PSA including age specific cut-offs, PSA density, PSA velocity, and PSA 
doubling time.5,6 
PSA was initially approved by the American Food and Drug Administration (FDA) for 
monitoring men with prostate cancer in 1986 and subsequently as a diagnostic marker 
in 1994. With the increased ability to detect early disease, a stage migration was seen in 
countries with high uptake of PSA screening with an increased diagnoses among 
younger men with lower stage disease.7  
Two landmark studies changed the landscape of PSA screening. The Prostate, Lung, 
Colon, and Ovary Trial (PLCO) was commissioned by the American National Cancer 
Institute in 1993 to examine the impact of systematic screening on cancer mortality. In 
the prostate cancer arm the study randomized over 76 000 men 55 to 74 years old 
randomized to annual PSA testing or no screening. After 7 years of follow-up prostate 
cancer was detected at a slightly higher rate of 116 per 10 000 person-years in the PSA-
screened group compared to 95 per 10 000 person-years in the unscreened group, 
however no difference in mortality was identified (rate ratio, 1.13; 95% CI, 0.75-1.70).8 
Subsequent re-evaluation of the PLCO data revealed heavy contamination – with up to 
90% of the control “unscreened” arm having undergone PSA testing at least once and 
over 90% having undergone screening during the trial.9 
In contrast, the European Randomized study of Screening for Prostate Cancer (ERSPC) 
was a 1993 study involving over 162 000 men aged 55 to 69 also randomized to PSA 
screening versus no screening. Ultimately, a 21% reduction in prostate cancer-specific 
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mortality was identified with the number needed to screen at 781 and the number 
needed to treat at 27. The study concludes the PSA screening can reduce high grade, 
locally advanced cancers, however this is at the risk of overdiagnosis.10 
The conflicting results of these studies and the implications of their results have led to 
fierce debates regarding the role of PSA in the early detection of prostate cancer. Based 
on the PLCO data the United States Preventative Services Task Force (USPSTF) 
recommended against PSA screening for the detection of prostate cancer in 2012, with 
the Canadian Task Force following in 2014.11,12 This subsequently resulted in  a stage 
migration of newly diagnosed prostate cancers in North America, with fewer, but higher 
grade cancers being detected.13,14 During this period incidence rates in white American 
men decreased over from 67 in 2010 to 48 per 100 000 men in 2016. Similar trends 
were seen among black (99 to 74 per 100 000 men) and men of other ethnicities (36 to 
28 per 100 000 men).15   
Presently, all major urologic societies, though many generalist societies and national 
task forces recommend against its use.11,12,16–19 Current recommendations note that no 
one true PSA cut-off exists for all individuals and instead encourages a shared decision-
making approach incorporating a patient’s age, family history, clinical exam and often 
the use of risk calculators in order to lead discussions with patients.16–18 
Digital Rectal Exam 
Digital rectal examination (DRE) involves a clinician physically examining the prostate for 
suspicious nodules, indurations, and asymmetries. Prior to PSA testing DREs was an 
essential tool for screening for prostate cancer. With a sensitivity of 0.51 and a 
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specificity of 0.59, its role was primarily driven by the lack of a suitable alternative as 
opposed to a definite clinical value.20 Many have questioned the role of initial and serial 
DREs in prostate cancer screening due to a lack of objective supportive data and a lack 
of clinical benefit.20,21 Although urologic societal guideline acknowledge the controversy 
most recognize the potential role in detecting significant disease.17,18(p1) 
Prostate biopsy 
Ultimately, the diagnosis of prostate cancer requires histologic confirmation with a 
prostatic biopsy. The prostate biopsy allows for the diagnosis of the histopathological 
subtype, pathological grade, location, volume and if identified, lymphovascular invasion 
and extraprostatic extension. Current standard of care involves ultrasound guided 
biopsy through either a transrectal or transperineal approach. Evolving technologies 
have allowed for improved imaging and sampling of the prostate using magnetic 
resonance imaging (MRI) guidance to identify lesions using either cognitive or fusion 
guided biopsy.22,23  
Grading, staging and risk stratification 
Once pathology is established, prostate cancers can be graded and staged, and patients 
can be risked stratified. Prostate cancers were traditionally graded based on their 
Gleason score, a composite of the two most abundant pathologic patterns observed. 
The Gleason score has recently been modified to the Gleason grade group to reflect 
more contemporary data and vernacular.24 
Prostate cancer is staged according to tumor, node, metastasis (TNM) classification 
(Table 1) and stratified into very high, high, intermediate, low and very low risk disease 
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based on the PSA, clinical stage, and grade group (Table 2).25 In efforts to improve 
clinicians’ abilities to prognosticate patients, the TNM staging has undergone multiple 
revisions, most recently in 2017.26 A patient’s risk, coupled with their clinical picture and 
performance status, allows clinicians to guide further investigations and treatment. 
Clinical Tumor 
T0 No evidence of primary tumor 
T1a 
T1b 
T1c 
Incidental histologic finding in <5% resected tissue 
Incidental histologic finding in >5% resected tissue 
Tumor identified by needle biopsy 
T2a 
T2b 
T2c 
Palpable in one half of one lobe or less 
Palpable in more than one half of one lobe, but not bilateral 
Palpable bilaterally 
T3a 
T3b 
Extraprostatic extension  
Invades seminal vesicle(s) 
T4 Fixed or invades adjacent structures other than seminal vesicles  
Pathologic Tumor 
T2 Organ confined 
T3a 
T3b 
Extra prostatic extension or microscopic invasion of bladder neck 
Seminal vesicle invasion 
T4 Fixed tumor or invades adjacent structures other than seminal 
vesicles 
Nodes 
N0 No positive regional nodes 
N1 Metastatic regional nodes 
Metastasis 
M0 No distant metastasis 
M1a 
M1b 
M1c 
Nonregional lymph node(s) 
Bone(s) 
Other site(s) 
Table 1. Tumor, node, metastasis staging of prostate cancer according to the American Joint 
Committee on cancer 8th edition based on clinical or histologic (pathology) findings.26 
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Risk Group Clinical/pathological features 
Very low T1c AND 
Grade group 1 AND  
PSA <10 ng/mL AND 
Fewer than 3 prostate biopsy fragments/cores positive, ≤50% cancer 
in each fragment/core AND 
PSA density <0.15 ng/mL/g 
Low T1-T2a AND 
Grade Group 1 AND 
PSA <10 ng/mL 
Intermediate Has no high or vary high risk 
features and has one or more 
intermediate risk factors 
(IRF): 
• T2b-T2c 
• Grade Group 2 or 3 
• PSA 10-20 ng/mL 
Favourable 
intermediate 
• 1 IRF 
• Grade Group 
1 or 2 AND 
• <50% biopsy 
cores positive 
Unfavourable 
intermediate 
• 2+ IRF 
• Grade Group 
3 and/or 
• ≥50% biopsy 
core positive 
High T3a OR 
Grade Group 4 or 5 OR 
PSA ≥20 ng/mL 
Very high T3b or T4 OR 
Primary Gleason pattern 5 OR 
>4 cores with Grade Group 4 or 5 
Table 2. Prostate cancer risk stratification according to National Comprehensive Cancer Network 
(NCCN) criteria.25 
Risk Factors 
Significant efforts have been made attempting to identify underlying genetic or 
environmental risk factors for prostate cancer. Unfortunately, few definitive and even 
fewer actionable factors have been discovered. Of all factors investigated only age, 
family history, ethnicity and certain genetic mutations have shown a consistent 
association with prostate cancer. 
An individual’s risk of prostate cancer has been shown to increase drastically with age. 
Autopsy studies have estimated the prevalence of prostate cancer to increase with each 
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decade, from 5% in men under 30 to over 40% in men over the age of 70 and nearly 60% 
in men over 80.27,28 However, given the slow growing and often indolent nature of the 
disease, prostate cancer screening is not recommended by any societal guideline in men 
with life expectancies under 10 years while some recommend against screening any 
man over the age of 70.16–18 
Family history positive for prostate cancer been shown to drastically increase the risk of 
developing prostate cancer. The son of an affected father has a relative risk (RR) of 
prostate cancer 2.17 times higher than an individual without an affected relative. The 
risk continues to increase with an affected brother (RR 3.37) or with more than two first 
degree relatives (RR 5.08).29 While the correlation between family history and prostate 
cancer has been considered  absolute, there has been a recent interest in exploring 
whether these men are any increased risk of aggressive disease. A large Swedish 
population-based study utilized their national prostate cancer database to determine 
the risk of developing low risk, non-low risk and high-risk prostate cancer in men with 
relatives diagnosed with prostate cancer. The study found that these men had a 30-60% 
probability of developing prostate cancer by age 75, however approximately half of 
these were low risk disease. Interestingly the risk of developing aggressive prostate 
cancer correlated with the risk of their relative’s disease and the number of family 
members affected, indicating a potential genetic predisposition for aggressive disease.30 
These observed increases have led most major urologic societies to encourage clinicians 
to consider earlier prostate cancer screening in men with family history of prostate 
cancer.16–18 
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While the familial risk of prostate cancer indicates some genetic component, hereditary 
mutations likely account for less than 15% of prostate cancers.31 Attempts to identify 
causative mutations have been met with mixed results, highlighting the potential 
polygenic nature of the disease with rare variants causing high risk disease.32 For 
example mutations to the BRCA2 gene is estimated to give a 5 to 7 fold risk of 
developing prostate cancer, while only present in <1% of the general 
population.33,34,35(p1) Ongoing research continues to identify potential mutations 
involved in prostate cancer mutagenesis, however few actionable discoveries have been 
identified. 
Significant efforts have been placed both retrospectively and prospectively to identify 
modifiable risk factors of prostate cancer. Small or retrospective studies identify a 
potential novel target; however, the larger or confirmatory studies fail to show 
conclusive results (Table 3).  
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 Risk Factor Observed impact 
Androgens CAG repeat polymorphism on androgen receptor increases risk of 
prostate cancer (OR 1.2-1.3), but no relation between serum 
androgens levels and prostate cancer risk.37,37 Finasteride 
(medication affecting the androgen pathway) decreases risk of 
prostate cancer, but increases the detection of high grade disease.38 
Estrogens Low incidence of prostate cancer in cultures, vegetarians with high 
intake of phyto-estrogens39 
Polymorphism in estrogen-related genes associated with increased 
risk of prostate cancer (OR 1.26-1.63)40 
Inflammation and 
infection 
Chronic inflammatory response leading to dysplasia, 
hyperproliferation, DNA damage. Premalignant lesions seen on 
histology.41 
Insulin-like growth 
factor axis 
High serum insulin levels associated with increased risk of prostate 
cancer.42 
IGFBP-2 may promote cell growth, resistance to chemotherapy, but 
does not affect risk of developing prostate cancer.43,44 
Leptin High leptin concentration in men with high volume, advanced 
disease.45,46 
Obesity Weak positive association with aggressive disease (RR 1.05 per 5 
kg/m2) potentially through insulin, insulin-like growth factor-1 and 
leptin42,45,47  
Sexual activity No impact of age of first intercourse, marriage 
Increased risk with increased frequency (>3 per week, RR 1.2)48 
Sexually transmitted 
infections 
Increasing number of partners increases risk of prostate cancer (>20 
partners, RR 1.2)48 
Increased risk with history of STI (OR 1.6) and history of multiple 
STDs (>3, OR 3.3)49  
Smoking No increased incidence, but may have a role in lethality, 
biochemical recurrence, and disease progression.50–52 
Vasectomy Increased risk of prostate cancer post vasectomy (RR 1.4-1.6), 
though the risk disappears with proper patient matching.53–56 
Vitamin D 
Vitamin D receptor 
Higher incidence of prostate cancer in northern latitudes, prostate 
cancer mortality inversely related to UV exposure, but no impact of 
vitamin supplementation.57–59 
Vitamin E Supplementation may increase (HR 1.17) or have no impact on 
prostate cancer risk.60–62 
Table 3. Selected risk factors for prostate cancer showing inconclusive results. OR: odds ration; 
DNA: deoxyribonucleic acid; RR: relative risk; IGFBP-2: insulin-like growth factor-binding protein 
2; STI: sexually transmitted infection. 
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Incidence 
Prostate cancer is the second most commonly diagnosed male cancer worldwide, 
accounting for 14.5% of all malignancies in men, second only to lung cancer.63 It is the 
most commonly diagnosed cancer in 105 countries and the leading cause of cancer 
death in 46 countries. Globally, prostate cancer is responsible for 1.3 million new cases 
and 359 000 deaths annually.63 Varied rates of prostate cancer are seen, with rates 
highest in Europe and North America and lowest in South-East Asia.63 Efforts to 
understand the cause of these variable rates have met significant resistance controlling 
for genetic, geographic, and social confounding variables. 
To address the uncertain etiology of prostate cancer one approach would be to compare 
incidence rates between countries. Identifying a population with aberrant cancer risks 
could allow one to investigate the potential protective or contributory factors. 
Unfortunately, attempts to objectively study the cause for the varied rates are hindered 
by multiple obstacles - most notably by the paucity of high-quality data and variable and 
fluctuating rates of PSA screening. 
Data sources and estimates 
The Cancer Incidence in Five Continents (Volume X) is an investigational report 
published by the International Agency of Cancer and International Agency for Research 
on Cancer (IACR) aiming to publish comparable population-level cancer data to allow for 
international comparisons.64  Given their mandate to publish strictly high-quality data, 
over 20% of their received data was rejected. This resulted in a disproportionate 
underrepresentation of developing and African countries and an overrepresentation of 
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developed and predominantly Caucasian countries. The latest volume captures only 14% 
of the world’s population, including 2% of African, 6% of Asian, and 8% of Central and 
South American populations. Whereas 95% of North American, 78% of Oceanic, and 
42% of European populations are included.64 
Given this paucity of a high-quality comparative data the IACR worked in conjunction 
with the World Health Organization (WHO) to establish GLOBOCAN as a method to 
report best available data. Currently, GLOBOCAN provides estimates of cancer incidence 
and cancer-specific mortality for 184 countries. GLOBOCAN utilizes nine methods to 
estimate cancer incidences with varying degrees of accuracy ranging from the utilization 
of national incidence databases (highest quality) to average estimation from 
neighbouring countries (lowest quality).65 This uncertainty of data quality makes 
translation of true cancer incidence and mortality difficult. Alternatively, the use of 
national databases with diverse populations allows one to observe rates within 
communities and allows for comparisons between groups with more similar geographic 
and social exposures. The American Surveillance, Epidemiology and End Results (SEER) 
program covers nearly 35% of the American population with reasonable representation 
from white, African American, Hispanic, and Asian populations allowing for comparisons 
of ethnic rates within a single system.15 
GLOBOCAN estimates prostate cancer to have a world-wide age standardized incidence 
ratio per 100 000 men (ASIR) of 29.3. Estimates vary widely from 11.5 in Asia to 73.7 and 
79.9 in North America and Oceania respectively (Figure 1).63 The nations with the 
highest ASIR were the French Caribbean islands of Guadeloupe (189.1) and Martinique 
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(158.4) followed by Ireland (132.2). Lowest rates were reported in Bhutan (1.0), Nepal 
(1.1) and Yemen (1.8).18 Similarly, SEER estimates the highest rates in American black 
men and lowest rates in Asian men.15 
The Prostate Cancer in Ethnic Subgroups study (PROCESS) performed in the United 
Kingdom looked at a cohort of men diagnosed with prostate cancer between 1997 and 
2001 in London and Bristol. They demonstrated a prostate cancer incidence rate 3 times 
higher in black men compared to white men, with no difference between black men of 
African and Caribbean descent.66 
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Figure 1. Variation of age standardized rates of prostate cancer incidence by country. ASR: Age 
standardized rate. IARC: International Agency for Research on Cancer. Source: GLOBOCAN 201867 
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Impact of PSA on prostate cancer incidence 
With the adoption of PSA-based screening there has been an increased detection and 
subsequent stage migration of prostate cancers as patients more often present with 
lower grade and organ-confined tumors.7 This resulted in marked spike in prostate 
cancer incidence in countries as screening rates rose. Rates of prostate cancer quickly 
spiked in the United States in both white men (ASIR 35.8 to 79.2) and black men (ASIR 
58.1 to 121.6) between 1985 and 2000 (Figure 2. Age-standardized incidence rate of 
prostate cancer among white (blue), black (orange), and men of other ethnicities (grey) 
in the United States from 1975-2016. Rates are per 100 000 and age-adjusted to the 
2000 United States Population (single ages to 85+) standard. Source: SEER 9.15Figure 2).15 
This rate subsequently fell to 47.6 in white men and 74.0 in black men following 
recommendations by the USPSTF initially against PSA for prostate cancer screening in all 
men (D recommendation) in 2008 and 2012 to individualized screening in select men 
after discussing the risks and benefits (C recommendation) in 2018.12,68,69 A similar 
pattern of prostate cancer incidence can be seen in the Canadian population (Figure 
3).70 While PSA screening has been adopted more heavily in North America, lower, 
delayed and variable rates are seen in Europe and Asian countries.71 Currently, Japan is 
the only Asian country with guidelines on prostate cancer screening, advocating for a 
shared decision making approach as of 2008.72,73 Despite its significant impact on the 
region, sub-Saharan African countries have shown low uptake of PSA screening and poor 
overall awareness of the risks of prostate cancer.74–76 Most South and Latin American 
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governing bodies recommend against PSA screening, while Mexico recommends 
screening men over 50 years of age.77 
 
Figure 2. Age-standardized incidence rate of prostate cancer among white (blue), black (orange), 
and men of other ethnicities (grey) in the United States from 1975-2016. Rates are per 100 000 
and age-adjusted to the 2000 United States Population (single ages to 85+) standard. Source: 
SEER 9.15 
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Figure 3. Age-standardized incidence and mortality, number of cases and deaths from prostate 
cancer in the pre and post PSA era in Canadian men, 1969-2009, Canada. Source: Dickinson et al 
2016.70 Reprinted with permission. 
Using prostate cancer incidence as a comparator 
The changing landscape of PSA screening and its subsequent impacts of prostate cancer 
incidence limits the ability to use prostate cancer incidence as a global and temporal 
comparator of prostate cancer between countries and over time.71,78 Similar difficulties 
exist when trying to use prostate cancer incidence within countries due to varied 
screening rates and beliefs within communities.79,80 When using incidence alone, it is 
unclear whether the increased rates observed in African and Caribbean nations are due 
to inherent genetic risks of prostate in these men, a shared environmental exposure, 
increased systemic screening, or a combination of these variables and more. Overall, the 
current academic consensus appears to mirror published GLOBOCAN and SEER 
estimates with men of African descent believed to be at higher risk, while men of Asian 
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descent are at lower risk, though the underlying data and strength of these 
recommendations remain questionable. 
Mortality 
Prostate cancer is the 6th leading cause of cancer related death worldwide, accounting 
for 7% of all cancer deaths.63 GLOBOCAN data estimates prostate cancer to be the 
leading cause of male cancer-specific mortality in 53 countries with nearly 360 000 
deaths from prostate cancer in 2018 (Figure 4).63 In Canada 4200 men are expected to 
die of prostate cancer in 2020, accounting for 1 in 9 cancer related deaths.1 
Global data sources and estimates 
Like the disparities seen in the incidence of prostate cancer, varied rates of prostate 
cancer-specific mortality are observed worldwide. Using the GLOBOCAN database, age 
standardized mortality rates (ASMR) of prostate cancer range from highs of 48 and 42 
per 100 000 men in Barbados and Jamaica to less than one in Yemen and Napal.63 
Unfortunately, it has been exceedingly difficult to separate sociocultural impacts on 
access to medical care from true genetic and environmental risk factors for disease.  
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Figure 4. Global map of the most common cause of male cancer mortality by country in 2018. 
The number of countries represented are noted. ASR: Age standardized rate. IARC: International 
Agency for Research on Cancer. Source: GLOBOCAN 2018.67 
The most extensive comparison of cancer survival across countries began in 1999 as a 
collaboration between the American Centers for Disease Control and Prevention and the 
British Department of Health and Cancer Research UK. It was initially established to 
investigate differences in cancer survival between European and American individuals 
diagnosed with prostate, breast, and colorectal cancers between 1990 and 1994.81 This 
project evolved into the cancer survival in five continents (CONCORD). It is the first 
global comparison of cancer survival involving population-based cancer registries from 
all five continents covering nearly 300 million individuals. 
Given the differences in life expectancy across the globe, CONCORD estimated relative 
survival as the ratio between observed mortality and expected mortality. Expected 
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mortality rates were calculated by creating life tables for each population studied, 
controlling for sex, region, and race.82 
The original CONCORD study identified marked differences in prostate cancer survival 
across ethnically similar countries of equivalent Human Development Index and even 
different regions within countries (Figure 5). Across Europe, 5-year survival in men 
diagnosed with prostate cancer between 1990-1994 ranged from as low 37% in Poland 
to highs of 86% in Austria. While not as drastic, geographic differences are seen in 
Canada and the United States, ranging from 78% in Saskatchewan to 89% in British 
Columbia and from 86% in New York to 93% in Atlanta.81  
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Figure 5. National differences in age standardized 5-year relative survival of men diagnosed with 
prostate cancer from 1990-94. Source: CONCORD Study 2008.81 Reprinted open source figure. 
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The CONCORD-3 is the most recent update encompassing nearly 1 billion individuals, 18 
cancers and 322 registries across 71 countries. This 2018 update estimates cancer 
survival from 2000 to 2014 and used a similar approach to CONCORD and CONCORD-2, 
estimating relative survival after calculating background mortality risk utilizing life 
tables. The CONCORD-3 showed an overall trend of improved 5-year prostate cancer 
survival, especially amongst developed nations. A total of 41 countries had 5-year net 
prostate cancer survival rates over 90% and a further 17 in the 80-89% range. Canada 
specifically improved from 85% between 1990-1994 to 94% in 2010-2014 (Figure 6).81,83  
Unfortunately, no CONCORD study has been able to capture high volume African or 
Asian data. Only 6 African countries submitted data to CONCORD-3 and only 2 700 men 
were ultimately included in the study. Of the men included, 4.3% were lost to follow up 
and 37% were censored. Asian countries had better overall representation in CONCORD-
3 with 397 000 men included, however 42% of these men were from Japanese registries. 
This is compared to 2 700 000 North American and 2 300 000 European men. Of the 
African data available, majority is single centre data with poor generalizability. 
CONCORD provides the ability to trend mortality over time, which provides useful 
information to track initiatives and improvements within a country. However, the lack of 
standardized treatment and screening practices and low proportion of African (<2%) and 
Asian (<6%) men captured by high quality population-based registries limit the ability to 
compare between ethnically distinct countries.64 This leads to uncertainty whether the 
high rates of prostate cancer mortality seen in African nations are due to the underlying 
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genetic risk factors in the population, access to healthcare, or environmental exposure 
to an unknown risk factor.  
 
Figure 6. Changes in 5-year net survival in adults diagnosed with prostate cancer over 5-year 
periods by country. *Data with 100% coverage of national population. †National estimates not 
age standardised. §Estimates flagged as less reliable source. Maroon: South America. Red: North 
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America. Yellow: Asia. Blue: Europe. Green: Oceania. Grey: Africa. Source: CONCORD-3.83 
Reprinted with permission. 
National estimates of prostate cancer mortality 
An alternative to using international data is to study the impact of ethnicity on prostate 
cancer within a country with diverse populations and population-based datasets. Many 
comparators use the easily accessible American SEER database, however one must 
acknowledge its inherent biases and inability to fully control for confounders – most 
notably socioeconomic status and access to care in the United States.84,85  
Analysis of the CONCORD study and the SEER database reveals a trend of increased 
mortality among black American men with a 5-year survival of 86%, compared to 92% in 
white men. This trend remained consistent across states, with the difference between 
white and black prostate cancer survival ranging from 5% in Florida to 16% in Rhode 
Island.81  
Miller et al. used the SEER as well as state-specific databases to investigate the 
incidence and mortality rates among American Asian and Pacific Islander communities. 
Age-adjusted mortality rates among Asian communities were consistently ⅓ to ½ lower 
than non-Hispanic white men. Lowest rates were seen in Korean and Japanese men at 
11 and 18 per 100 000 compared to 28 per 100 000 for non-Hispanic white men.86 
Using England’s population-based mortality datasets linked to hospital censuses and 
records have allowed the investigation of the lifetime risk of dying of prostate cancer in 
the United Kingdom. It found the lifetime risk of both being diagnosed with and dying 
from prostate cancer was doubled in black men compared to white men. In the same 
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study Asian men demonstrated lower lifetime prostate cancer incidence (8% vs 13%) 
and mortality (2% vs 4%). A significant limitation was the inaccuracy and absence of 
accurate ethnicity data, necessitating multiple assumptions be made.87 
Using prostate cancer mortality as a comparator 
In contrast to the fluctuations seen in prostate cancer incidence, prostate cancer 
mortality in Canada has remained more stable over time with approximately 3000 
deaths per year and an ASMR that progressively decreased from 45 in 1992 to 26 in 
2015 (Figure 7).88 This stability makes prostate cancer mortality a more reliable 
temporal marker to investigate the impacts of ethnicity and immigration on prostate 
cancer mortality. 
 
 
Figure 7. Number of prostate cancer deaths and age-standardized mortality rate in Canada from 
1992 to 2015. ASMR: Age-standardized mortality rate. Source: Leblanc et al. Reprinted open 
source figure.88 
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Impact of immigration on prostate cancer 
Many studies have attempted to use population-based registries to compare prostate 
cancer mortality between nations in hopes of identifying at-risk and protected groups. 
An alternative method to a investigate cancer’s etiology is through immigration studies. 
Comparing an immigrant population to their home country assesses the impact of 
different environments on genetically similar individuals. In contrast, comparing 
immigrant populations to their host countries assesses the impact of the same 
environment on genetically differing populations.  
Immigration studies are most useful when there is a notable difference in the 
dependent variable – either largely different environments or genetic pools. While these 
studies can address a wide range of questions, a unique niche has been developed 
investigating more nuanced, or multifactorial determinants of cancer risk. 
An early immigration study involving Statistics Canada datasets investigated the rates of 
cancer mortality among the six largest immigrant populations in Ontario from 1969 to 
1973. It found no appreciable difference in cancer mortality in the Canadian population 
compared to the British, Italian, German, Dutch, Polish, and Soviet immigrant groups.89  
A 2007 study used the SEER database to compare prostate cancer incidences among 
Korean-Americans compared to native South Koreans as the risk amongst South Koreans 
in among the lowest in developed nations with age standardized incidence rates of 5-6 
per 100 000 men.90 It found Korean-American immigrants had increasing risks of 
prostate cancer compared to native Koreans, however the risks did not reach that of 
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white Americans. This suggests a potential environmental driver of prostate cancer 
through westernization, though the exact mechanism is yet to be determined. 
Many of the more thorough immigration studies have been performed in Sweden by 
leveraging their high-quality, population-based datasets with extensive demographic 
and medical data. A 2009 study compared the risk of prostate cancer amongst Swedish 
born and foreign born men from 1961 to 2004.91 Foreign born men had incidence rates 
43% lower than the Swedish population, however a significant time effect was observed. 
Men who immigrated greater than 35 years prior had a risk of prostate cancer closer to 
that of the native Swedish population compared to those with less time in Sweden 35 
years.   
Perhaps most intriguing as it contradicts the notion that African men are at increased 
risk of early and aggressive disease was a 2013 Swedish database study. The study 
involved over 690 000 first generation immigrants to Sweden with over 13 000 cases of 
prostate cancer identified. It demonstrated men of Middle Eastern, Asian, North African, 
and Chilean descent had not only a lower risk of developing prostate cancer, but also 
had higher disease specific survival (hazard ratio 0.6). The authors conclude that these 
discrepancies seen cannot be accounted for by observed clinical features or risk factors 
and that an underlying protective mechanism may be at play.92 
Canadian immigration and ethnicities 
Canada is uniquely situated to investigate the impacts of ethnicity and immigration on 
cancer. With nearly 250 000 economic immigrants, sponsored immigrants, and refugees 
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arriving yearly, the Canadian population is comprised of over 250 unique ethnic 
origins.93,94 The proportion of immigrants grew from nearly 20% in 2006 to 22% in 2016 
and is expected to reach over 25% by 2031.93,95 
Three major waves of immigration helped define the Canadian landscape. The first wave 
in the early 1900s comprised primarily of white European farmers attracted to the 
Canadian government’s offer of free land to settle western Canada. A second more 
heterogeneous, but still predominantly white wave occurred in the 1930-1950s 
coinciding with the Great Depression and World War II. The third wave began in 1962 
and continues to this day with changes to Canadian immigration policy to encourage 
immigration from non-European countries. Most importantly the policy changed the 
primary admission criteria from race and country of origin to skills and potential 
productivity.96,97 Changes to ethnic restrictions on Canadian immigration laid the 
foundation for Canada to become the diverse nation seen today. Allowing economic 
immigrants resulted in a sharp increase in the number of Black Canadians with 300 000 
West Indie immigrants and 150 000 African immigrants arriving between 1950-1995.98 
The healthy immigrant effect 
One major caveat to the interpretation of immigration studies is the healthy immigrant 
effect. The principle of the healthy immigrant effect is that those who are ill and 
infirmed are both less likely to seek out immigration opportunities and less likely to be 
welcomed by accepting countries. This leads to the selection of an immigrant population 
that is on average healthier than the standard population.  
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This effect has been clearly demonstrated in the Canadian population with both lower 
all-cause age standardized mortality rates for immigrant men (1006 vs 1305 per 100 000 
person-years) and women (610 vs 731 per 100 000 person-years) and lower all-site 
cancer risk (standard incidence rates 0.25-0.31).95,99 
For often debated reasons the healthy immigrant effect diminishes over time. It is 
thought that a combination of new life stressors, unhealthy western diet and the 
adoption of new risky behaviors like tobacco, alcohol, and illicit drug use may play a 
predominant role in weakening the initially protective effects.100–102 While the root 
causes of the healthy immigrant effect may be beyond the scope of this paper its impact 
must not be ignored. 
Canadian Cancer Registry 
Statistics Canada has been the custodian of Canada-wide cancer statistics since 1969, 
beginning with the National Cancer Incidence Reporting System (NCIRS). Initially the 
NCIRS was an event-based registry involving nine of ten provinces, with Ontario joining 
in later years.103 Since 1992, Statistics Canada has adopted a person-oriented database 
now known as the Canadian Cancer Registry (CCR). The CCR is an amalgamated registry 
maintained by Statistics Canada with data from the 10 Canadian provinces and 3 
territories registering all primary cancer diagnoses.104 The advantage of a person-
oriented database is the ability to longitudinally track individuals over time. These 
records can subsequently be linked to mortality data, allowing for calculation of cancer 
incidence and survival over time. While the registry is an excellent resource for clinicians 
and healthcare leaders in Canada, it provides limited demographic data to allow for 
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detailed exploration of potential underlying risks and trends in Canadian 
subpopulations. 
Canadian Census Health and Environment Cohort   
To address the deficiency of health data with detailed demographic statistics, Statistics 
Canada commission the Canadian Census Mortality and Cancer Follow-Up cohort. This 
was the first study of its kind to investigate the impact of sociodemographic factors on 
cancer incidence, morbidity, and mortality in Canada. The study linked the 1991 long 
form census, Canadian mortality database (CMDB), Canadian Cancer Database (CCDB) 
and annual tax files allowing the analysis of detailed health and demographic data 
between 1991 and 2001.105 The study found marked differences in mortality races based 
on education, socioeconomic status, and ethnicity.106 
The Canadian Census Health and Environment Cohort (CanCHEC) expanded on the 
Mortality and Cancer Follow-Up cohort by including data from the 1991 long-form 
censuses, the 2011 National Household Survey, the Canadian Vital Statistics Death 
Database, the Canadian Cancer Registry, the Discharge Abstract Database, the National 
Ambulatory Care Reporting System, and postal code files. Table 4 shows selected 
variables of interest provided by each dataset. More detail and the methodology of 
dataset linkages having been extensively documented by Peters et al and Wilkins et 
al.105–107   
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Dataset Relevant variable available 
1991 Long form census Age 
Ethnicity 
Immigration status 
Country of birth 
Education 
Income 
Historic Tax Summary 
Files 
(1984-2011) 
Postal code 
Tax filings for censoring 
CCR 
(1992-2015) 
Primary malignant tumor diagnosis 
Age at diagnosis 
Tumor characteristics 
CVSDD 
(1991-20011) 
Cause of death 
Date of death 
Age at death 
Table 4. Sources of select analyzed variables in the 1991 CanCHEC database. CCR: Canadian 
cancer registry. CCDB: Canadian cancer database. CVSDD: Canadian Vital Statistics Death 
Database. 
1991 Long Form Census 
The 1991 Canadian Census of Population was administered to all Canadians on June 4, 
1991 and ultimately covered over 96% of the Canadian population. The individuals not 
captured were estimated to be primarily young, mobile, low income, Aboriginal, or 
homeless.106  The census included a mandatory short-form portion administered to all 
respondents that included basic demographic and family data and a long-form portion 
administered to 20% of eligible respondents. The long-form questionnaire included 
respondents age, detailed ethnic data including home language, religion, ethnic origin 
and place of birth, education, employment, and economic data. Linkage within the 
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CanCHEC specified individuals must be aged 25 or older at the time of the census with 
taxes filed in 1990 or 1991. Individuals who were institutionalized were also excluded.  
Historic Tax Summary Files 
The T1 family file covers 96% of the Canadian population and includes basic tax and 
demographic data including annual income, age grouping, and postal code and is 
updated annually.108,109 To form the T1 family file an individual’s T1 tax return, T4 tax file 
and federal child benefit (where applicable) are combined and used to attribute non-
filing spouses, partners, and children. The data is collected by Canada Revenue Agency 
(CRA) and reported to local and national bodies including Statistics Canada.  
The historic tax summary files included in CanCHEC allow for the longitudinal tracking of 
individuals regardless of name changes or movement throughout the country. These 
files also allowed for accurate censoring of individuals due to death or emigration.  
Canadian Cancer Registry  
The Canadian Cancer Registry (CCR) is a collated registry collecting administrative data 
from the 10 provincial and 3 territorial cancer registries. It contains cancer data on all 
permanent and non-permanent residents of Canada and has been reported annually 
since 1992. The CCR is maintained by the Canadian Council of Cancer Registries, a 
collaboration between the provincial and territorial cancer registries and Statistics 
Canada. The council standardizes and codifies the reported elements of the CCR. 
As a person-based registry the CCR is able to longitudinal track an individual and 
includes all primary cancer diagnoses over a patient’s lifetime.104 It includes all primary 
borderline and malignant tumors classified according to the International Statistical 
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Classification of Diseases and Related Health Problems (ICD 9 and 10 where applicable). 
The CCR also includes tumour characteristics and basic demographic data.  
Canadian Vital Statistics Death Database 
The Canadian Vital Statistics Death Database (CVSDD) is updated annually and tracks 
deaths of Canadian residents and non-residents who died in Canada. The database has 
been maintained by Statistics Canada since its first publication in 1921 and has gradually 
included progressively more comprehensive data. Its most recent updates include data 
from all provinces and territories and classifies causes of death according to ICD criteria. 
Until 2010 the database also included Canadians who died in American states, however 
this practice has since been discontinued.110 
The database is made possible by mandatory collection, classification, and reporting of 
all deaths within provinces and territories. These results are subsequently 
communicated by appropriate bodies to Statistics Canada. The CVSDD reports patients’ 
demographic and death data including birthplace, date of death, age at death, cause of 
death, location (province or territory at time of death), and autopsy data where 
appropriate.  
Summary and rationale 
The incidence and mortality of prostate cancer continues to evolve worldwide. It is 
unclear whether these changes are through direct genetic impacts, shared 
environmental exposures, or systemic differences in healthcare practices and access. 
Previous attempts to answer these questions have been limited by poor quality data and 
confounding variables. Ultimately, this provided mixed results and uncertain 
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conclusions. Overall, these studies appear to suggest increased risks of prostate cancer 
mortality among black men and decreased risk among Asian men, though the underlying 
cause of these differences is unknown.  
With the recent release of a Canada-wide database linking demographic, economic and 
health data we can explore ethnocultural impacts on cancers in Canada. Access to the 
CanCHEC dataset provides the unprecedented ability to longitudinally tract 20% of the 
Canadian population over an 18-year period. This leverages Canada’s diverse and 
immigrant heavy population, as well as its universal access to care to investigate the 
impact of ethnicity and immigration on prostate cancer mortality in Canada.  
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CHAPTER 2:  
Aims and Hypotheses 
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The primary purpose of this study was to investigate the impact of ethnicity and 
immigration on prostate cancer mortality in Canadian men. The findings are presented 
as an integrated article with two independent manuscripts. The specific aims and 
hypotheses of each manuscript are presented below. 
Study 1: aims and hypotheses 
Chapter 3 presents the first study: The impact of ethnicity on prostate cancer mortality 
in Canada. This study utilizes the 1991 CanCHEC dataset to assess the relationship 
between ethnicity and prostate cancer – accounting for age, education, immigration 
status, and region. Given the strengths of the dataset, all cancer diagnoses between 
1992 and 2010 can be followed to death as long as the individual remained in Canada 
and continued to file taxes. This allows for the calculation and comparison of all-cause 
and cancer-specific mortality between different ethnic groups. The purpose of this study 
was to use Canadian data to reaffirm or challenge previous conclusions using population 
level data in an ethnically diverse, equal access healthcare system. 
Hypothesis 1 
We hypothesize that Asian-Canadian men will have a lower all-cause and cancer-specific 
mortality. Previous high quality population-level studies from ethnically homogenous 
Asian nations such as Japan and Korea, as well as American SEER dataset studies have 
consistently shown decreased prostate cancer mortality as compared to American or 
ethnically homogenous European and Scandinavian nations.63,90,92,111 These patterns 
hold true in both registry and immigration studies and appear to function independent 
of PSA screening rates.92,112 
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Hypothesis 2 
In line with previously published data and guideline recommendations, we hypothesize 
that black Canadians will have a higher all-cause and prostate cancer-specific 
mortality.16–18,113,114 As compared to studies investigating prostate cancer mortality in 
Asian, European, and Scandinavian men, studies focusing on prostate cancer mortality in 
black men struggle with confounding variables, most notably poor quality and access to 
care, socioeconomic barriers to healthcare, different treatment patterns, and high rates 
of comorbidities.115–117  
Study 2: aims and hypothesis 
The second study is presented in Chapter 4, Examining impact of immigration on 
prostate cancer mortality in Canada using the CanCHEC.  This study was performed 
using similar methodology to the first study. It uses the CanCHEC dataset in order to 
assess the impacts of immigration on prostate cancer mortality in men in Canada. Given 
the likely multifactorial nature of prostate cancer this study attempts to further explore 
potential biologic and geographic impacts on prostate cancer mortality by investigating 
cohorts of similar genetic profile in a new environment. If a genetic predisposition plays 
a dominant role than prostate cancer mortality should be similar to rates seen in home 
countries and remain stable over time. If environmental risk factors play a dominant 
role than rates should be lower on immigration and increase depending on length of 
stay in Canada. 
Hypothesis 1 
Given the multifactorial nature of prostate cancer, mortality rates in Asian immigrant 
men will initially be decreased compared to white Canadian men, however these rates 
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will increase over time. This is in line with what has been seen in American studies using 
the SEER dataset where rates in Asian men approach, but never eclipse the rates seen in 
white men.90  
Hypothesis 2 
Similarly, we hypothesize that immigrant black men will have a higher rate of prostate 
cancer-specific mortality. While majority of the studies have been observational and 
retrospective this community is believed to be at higher risk for early and aggressive 
disease.16–18 We expect this rate to progressively decline over time, but remain elevated, 
given the presumed genetic predisposition to aggressive disease. 
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CHAPTER 3:  
The impact of ethnicity on prostate cancer 
mortality in Canada 
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Abstract 
Purpose: Prostate cancer is one of the most common non-cutaneous cancers diagnosed 
worldwide. Attempts to identify at risk populations have shown men of Asian descent to 
be protected, while men of African and Caribbean descent appear to be at an increased 
risk, though the cause of this disparity is largely unknown. It is unclear whether there is 
genetic, geographic, or social factors influencing prostate cancer mortality in these 
communities. The diverse Canadian population, single-payer healthcare model, and 
Statistic’s Canada’s population-level data lends itself well to investigate the impact of 
ethnicity on prostate cancer mortality. 
Methods: Using Statistics Canada’s Canadian Census Health and Environment Cohort 
(CanCHEC) we identified all men diagnosed with prostate cancer between 1992-2010. 
Cox proportional-hazards models were used to calculate hazard ratios (HR), predicting 
the association between the survival time of those with prostate cancer and ethnicity, 
controlling for age, immigration status, education, and province/territory. 
Results: 51 530 cases of prostate cancer were identified with 21 785 705 total deaths 
and 7 925 deaths caused by prostate cancer. On multivariate analysis South Asian (HR 
0.53 CI 0.36-0.76 p=0.0006) and East Asian (HR 0.62 95% CI 0.49-0.78 p=<0.0001) men 
had lower risks of prostate cancer-specific compared to non-visible minority men. No 
increased risk of prostate cancer mortality was seen in Black Canadian men (HR 0.83 
95% CI 0.67-1.02 p=0.068). A higher level of education and location in Canadian had 
significant impacts on prostate cancer mortality. 
43 
 
 
 
Conclusion: In our Canadian cohort, black ethnicity does not confer increased risks of 
prostate cancer mortality while South and East Asian men appear to have factors 
protective against prostate cancer mortality. 
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Introduction 
Prostate cancer is the most common non-cutaneous cancer in the Western world with 
an estimated 1 in 9 Canadian men expected to be diagnosed over their lifetime and 1 in 
29 are expected to die from prostate cancer.1 Despite extensive research, the only well 
established and accepted risk factors for prostate cancer remain age, family history, 
ethnicity and certain genetic mutations. Men of Asian descent appear to have lower 
rates and less aggressive disease while men of African descent have been demonstrated 
to have earlier onset, more aggressive disease with prostate cancer-specific mortality 
rates 80% higher than the white population.114,118,119  
Internationally, prostate cancer mortality rates vary widely with rates nearly four times 
higher in African nations compared to Asian nations.120 Unfortunately, it has been 
exceedingly difficult to separate the impacts of social, cultural and economic barriers on 
access to medical care from true genetic and environmental risk factors for the disease.  
The purported increased risk of early, aggressive disease have led to the classification of 
men of African descent as high risk by the both American and European urologic 
associations with subsequent recommendations of more aggressive screening practices 
in these men.16,18 However, the underlying data for these recommendations lacks high 
quality evidence, leaving the foundation for these recommendations uncertain. Some 
suggest that adjusting for nonbiologic differences including screening practices, 
socioeconomic status and access to healthcare may account for the disparities seen in 
the black population and recommend caution when drawing conclusions from these 
observational studies.84,85,116 
45 
 
 
 
Canadian data is uniquely suited to contribute to determining the impacts of ethnicity 
on prostate cancer mortality due in part to its diverse population and universal 
healthcare model. Using the Canadian Census Health and Environment Cohort 
(CanCHEC) we investigated the impacts of sociodemographic factors and their impacts 
on cancer mortality over an 18-year period. While causal linkages are not possible with 
population-based studies they can add high quality data to the question of ethnic 
impacts on prostate cancer mortality. 
Methods 
Study Design: This retrospective cohort study uses the 1991 CanCHEC to investigate the 
role of ethnicity on the likelihood of dying among those with prostate cancer in Canada 
between 1992 and 2010. 
Data source: The 1991 CanCHEC is a population-based database including data from the 
1991 long-form censuses linked to the Canadian Cancer Registry (1992-2010), Canadian 
Vital Statistics Death Database (1921-2016), and historic tax summary files (1984-2011), 
amongst others.121 Further detailing of the CanCHEC as well as its linkage methodology 
is thoroughly described by Peters et al.107  
Patient population: This study included all men involved in the 1991 long form census 
with complete demographic data diagnosed with prostate cancer between 1992 and 
2010. A diagnosis of prostate cancer was established using the International 
Classification of Disease coding of 185 before 2000 (ICD-9CM) and C61 from 2000 
onwards following the update to ICD-10-CM. As a person-oriented dataset, individual 
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cancer diagnoses and deaths are reported annually and linked. Individuals with missing 
demographic data and prostate cancer diagnoses prior to 1992 were excluded.  
Variables: Our focal independent variable was ethnic minority group as determined 
from responses to the 1991 Census. Categoric grouping was necessary to ensure 
adequate sample size to adhere to Statistics Canada reporting guidelines in accordance 
with the 1985 Statistics Act.122 The ethnic minority groups were categorized into 6 
groups as (1) Black (2) South Asian (3) East Asian (Chinese, Korean, and Japanese) (4) 
Southeast Asian and Filipino (5) West Asian or Arabs, and (6) not a visible minority, with 
the non-visible minority group acting as a reference category for regression models. 
Control variables were immigrant status, age, education, and Canadian region of 
residence as determined from the 1991 Census. 
Statistical methods: Frequency distribution of all-cause and prostate cancer-specific 
mortality was calculated and chi-squared tests for independence were conducted for 
each contingency table. Cox Proportional-Hazards Models were also used to predict the 
association between the survival time of those with prostate cancer and our covariates. 
Hazard ratios, 95% confidence intervals, and p-values are reported. Both a univariate 
analysis testing the effect of each individual independent variable and multivariate 
analysis testing the effect of independent variables, while accounting for our control 
variables was performed. All analyses were conducted using SAS 9.4 and vetted prior to 
release in accordance with Statistics Canada Research Data Centre protocols. This study 
was approved by the institutional review board of the University of Western Ontario. 
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Results 
In total there were 51 530 cases of prostate cancer diagnosed between 1992 and 2010. 
29 705 of these men died with 7 925 of these deaths caused by prostate cancer. Table 5 
shows baseline characteristics of men with prostate cancer in our cohort.  
Table 6 and Table 7 show univariate and multivariate hazard ratios of death due to all 
cause and prostate cancer. Our univariate analyses show that all ethnic minority groups 
with prostate cancer were less likely to die from any cause and prostate cancer 
specifically than non-ethnic minorities. 
A similar trend was seen on multivariate analysis. After accounting for immigrant status, 
age, education and Canadian region of residence, Black (HR 0.76 95% CI 0.67-0.87 ), 
South Asians (HR 0.83 99% CI 0.69-0.99), and East Asian (HR 0.65 95% CI 0.57-0.74) men 
with prostate cancer were significantly less likely to die of any cause as compared to 
non-visible minorities. For prostate cancer-specific mortality, South Asian (HR 0.53 95% 
CI 0.0.36-0.76) and East Asians (HR 0.62 95% CI 0.49-0.79) were seen to be at lower risk 
compared to non-ethnic minorities. Interestingly, black men were shown to not be at 
increased risk of prostate cancer death with a lower risk of prostate cancer mortality on 
univariate analysis (HR 0.47 95% CI 0.39-0.58) and no significant difference in risk on 
multivariate analysis (HR 0.83 95% CI 0.67-1.02). 
A geographic disparity was demonstrated on multivariate analysis with the West Coast 
having a protective effect (HR 0.82 95% CI 0.77-0.87) and the prairie provinces having an 
increased risk (HR 1.081 95% CI 1.02-1.14). 
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Died from any death Died from prostate cancer  
(n=21 785) p-value (n=7 925) p-value 
Minority Categories   <.0001   <.0001 
       Not a visible minority           21 045                          7 675    
       Black                 235                                95    
       South Asian                 125                                30    
       East Asian                 215                                70    
       Southeast Asian and            
x     Filipino                   55    
                            15  
  
       West Asian and Arabs                 110                                35    
Immigrant Status   <.0001   <.0001 
       Not an immigrant           16 695                          6 130    
       Immigrant Status             5 095                          1 795    
Age Categories   <.0001   <.0001 
       25-34                   25                                20    
       35-44                 325                             185    
       45-54             1 740                             750    
       55-64             6 105                          2 225    
       65+           13 590                          4 750    
Education Categories   <.0001   <.0001 
       No high school           12 235                          4 420    
       High school             6 210                          2 270    
       Postsecondary non-
university 
            1 495  
  
                         575  
  
       University degree             1 845                             660    
Canadian Region   <.0001   <.0001 
       Central Canada           12 385                          4 520    
       East Coast             1 900                             665    
       Prairies             4 090                          1 645    
       British Columbia             3 390                          1 085    
       Territories                   25                                10    
Table 5. Baseline characteristics of men with prostate cancer who died of any cause or of 
prostate cancer in the CanCHEC between 1992 and 2010.  
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  Univariate  Multivariate 
  HR 95% CI 
p-
value  HR 95% CI 
p-
value 
Minority Categories  
(ref= Not a visible 
minority)              
       Black 0.422 0.371 0.48 <.0001  
0.76 0.67 0.87 <.0001 
       South Asian 0.494 0.415 0.588 <.0001  
0.83 0.694 0.988 0.0362 
       East Asian 0.601 0.525 0.688 <.0001  
0.65 0.567 0.744 <.0001 
       Southeast Asian    
x     and Filipino 
0.534 0.411 0.695 <.0001 
 
0.82 0.631 1.069 0.1438 
       West Asian and       
x     Arabs 
0.714 0.591 0.862 0.0004 
 
1.14 0.941 1.374 0.1842 
Immigrant Status  
(ref= Not an 
immigrant)            
       Immigrant Status 0.896 0.868 0.925 <.0001  
0.88 0.852 0.91 <.0001 
Age Categories (ref= 
25-34)            
       35-44 1.894 1.246 2.879 0.0028  
1.9 1.251 2.89 0.0026 
       45-54 4.666 3.106 7.01 <.0001  
4.53 3.015 6.806 <.0001 
       55-64 14.9 9.933 22.33 <.0001  
13.8 9.188 20.66 <.0001 
       65+ 58.35 38.93 87.46 <.0001  
52.9 35.27 79.28 <.0001 
Education Categories  
(ref= No high school)            
       High school 0.577 0.559 0.595 <.0001  
0.83 0.801 0.852 <.0001 
       Postsecondary    
x     non-university 
0.452 0.428 0.476 <.0001 
 
0.74 0.698 0.778 <.0001 
       University degree 0.361 0.344 0.379 <.0001  
0.61 0.576 0.636 <.0001 
Canadian Region  
(ref= Central 
Canada)            
       East Coast 0.995 0.948 1.044 0.8261  
0.95 0.902 0.995 0.0308 
       Prairies 1.069 1.032 1.107 0.0002  
0.98 0.943 1.012 0.1917 
       British Columbia 1.087 1.047 1.129 <.0001  
0.91 0.88 0.949 <.0001 
       Territories 0.729 0.492 1.079 0.1146   1.13 0.761 1.669 0.5502 
Table 6. Univariate and multivariate analysis of all-cause mortality in men diagnosed with 
prostate cancer between 1992-2010 in the 1991 CanCHEC. ref: Reference. HR: Hazard ratio. CI: 
Confidence interval. 
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   Univariate  Multivariate 
 
  HR 95% CI 
p-
value  HR 95% CI 
p-
value 
Minority Categories  
(ref= Not a visible 
minority)              
       Black 0.474 0.387 0.581 <.0001  
0.83 0.672 1.015 0.0683 
       South Asian 0.314 0.218 0.453 <.0001  
0.53 0.364 0.76 0.0006 
       East Asian 0.549 0.434 0.694 <.0001  
0.62 0.49 0.787 <.0001 
       Southeast Asian 
x     and Filipino 
0.447 0.277 0.722 0.001 
 
0.68 0.422 1.105 0.1201 
       West Asian and  
x     Arabs 
0.651 0.469 0.903 0.0102 
 
1.03 0.737 1.426 0.8827 
Immigrant Status  
(ref= Not an 
immigrant)            
       Immigrant Status 0.863 0.819 0.91 <.0001  
0.87 0.827 0.924 <.0001 
Age Categories (ref= 
25-34)            
       35-44 1.345 0.836 2.165 0.2219  
1.35 0.84 2.177 0.2136 
       45-54 2.507 1.584 3.967 <.0001  
2.45 1.548 3.877 0.0001 
       55-64 6.661 4.224 10.5 <.0001  
6.2 3.928 9.772 <.0001 
       65+ 23.49 14.91 37 <.0001  
21.5 13.61 33.81 <.0001 
Education 
Categories  
(ref= No high school)            
       High school 0.593 0.563 0.623 <.0001  
0.83 0.789 0.874 <.0001 
       Postsecondary      
x     non-university 
0.49 0.449 0.535 <.0001 
 
0.78 0.712 0.849 <.0001 
       University 
degree 
0.366 0.337 0.397 <.0001 
 
0.6 0.549 0.648 <.0001 
Canadian Region  
(ref= Central 
Canada)            
       East Coast 0.956 0.881 1.037 0.2742  
0.91 0.833 0.982 0.017 
       Prairies 1.177 1.113 1.246 <.0001  
1.08 1.021 1.144 0.0072 
       British Columbia 0.951 0.89 1.016 0.1358  
0.82 0.765 0.874 <.0001 
       Territories 0.796 0.426 1.485 0.4729   1.18 0.63 2.194 0.6119 
Table 7. Univariate and multivariate analysis of prostate cancer-specific mortality in men 
diagnosed with prostate cancer between 1992-2010 in the 1991 CanCHEC. ref: Reference. HR: 
Hazard ratio. CI: Confidence interval.  
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Discussion 
This longitudinal cohort study is the largest to assess the impact of ethnicity on mortality 
rates in Canadian men with prostate cancer. After controlling for potential confounding 
variables, non-visible minority Canadians were at the highest risk for all-cause and 
prostate cancer-specific mortality. South and East Asian men were found to have lower 
risks of prostate cancer-specific mortality while other ethnicities showed no significant 
increased risk or protection compared to the non-visible minority group. 
Our study demonstrated no increased risk of prostate cancer-specific mortality in 
Canadian black men. Black men have traditionally been classified as a high risk 
population with increased rates of early and aggressive disease.113,114 Unfortunately, the 
scarcity of high quality outcomes data on black men has led to the majority of these 
conclusion being drawn from American administrative datasets where controlling for 
confounding variables can be exceedingly difficult.84,85,123 This is especially important in 
American studies given that American black men are known to have lower 
socioeconomic status, higher rates of comorbidities, and are less likely to be offered 
definitive therapy as compared to a non-Hispanic white men.113,124,125 These concerns 
have led some to question whether black men are truly at increase risk of prostate 
cancer mortality or whether there are social and societal barriers driving the observed 
poor outcomes. 
The results of this study are consistent with recent pooled analyses of the American 
Surveillance, Epidemiology, and End Results Program (SEER), Veteran Affairs health 
systems data and randomized control studies, as well as single institution studies that 
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found no evidence of a racial predisposition to aggressive disease once confounding 
variables were controlled.116,125 Specifically, adjusting for nonbiological differences 
including socioeconomic status and access to healthcare eliminated the observed 
increased risk seen amongst American black men for prostate cancer-specific mortality.  
A significantly lower hazard ratio was seen among South and East Asian men on both 
univariate and multivariate analysis, while the protective effect of Southeast Asian and 
Filipino as well as Western Asian and Arab ethnicity seen on univariate analysis 
disappeared when confounding variables were accounted for. Published data on these 
populations remain controversial as well given mixed uptake of PSA screening in their 
home countries.111,126,127 Overall, Asian men are have been shown to be at lower risk 
with age adjusted mortality rates 2.3 times lower as compared to non-Hispanic white 
men though they may present later due to cultural and social barriers to healthcare 
access.128 There does appear to be further risk stratification within the Asian 
populations. Retrospective analysis of men undergoing hormone therapy showed 
improved overall and cancer specific survival in Japanese men compared to white 
men.129 This may indicate a potential underlying genetic or cultural protective factor 
with respect to tumor biology or response to treatment. 
There have been few studies investigating the geographic disparity of prostate cancer 
mortality in Canada. Using data published by the Canadian Cancer Society, projected 
age-standardized mortality rates vary from lowest in Quebec, Ontario, and British 
Columbia (20-22 per 100 000 men) to their highest in Saskatchewan, Manitoba and 
Newfoundland (28-30 per 100 000 men), though no statistical analysis have been 
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performed to indicate the significance of these values.130 Our data showed a small 
coastal protective effect with lower all-cause and prostate cancer-specific mortality seen 
in the East and West coast provinces once confounding variables were controlled, while 
Alberta and Manitoba showed slightly higher risk of prostate cancer-specific mortality.  
Several limitations to this study should be acknowledged. As with all population and 
administrative data, the retrospective nature and subsequent linkage of these datasets 
limits the ability to draw definitive causal conclusions. The inability to further stratify 
individuals beyond broad ethnic groups may miss variable rates within each subset. 
Additionally, the CanCHEC was unable to provide family history, PSA, or treatment 
modality that may act as uncontrolled confounders in the studied population. Finally, 
the absence of cancer grading, staging, pathology, and treatment data limit the ability to 
comment on potential variations on how different ethnicities present and are treated in 
Canada. This data has been added to later versions of the CanCHEC and will hopefully 
yield results in the coming years. This study is the largest Canadian cohort to investigate 
the impacts of ethnicity on prostate cancer mortality. The large sample size, long follow 
up, and equal access healthcare model provided the power necessary to overcome 
confounding social determinants of health observed in previous studies. 
Conclusion 
As compared to non-visible minority Canadian men with prostate cancer, black men 
showed no increased risk of prostate cancer-specific mortality. Black, South Asian and 
East Asian all had lower risks of all-cause mortality and South Asian and East Asian 
showed lower risks of prostate cancer-specific mortality. A slight geographic effect was 
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noted with lower risks of prostate cancer and all cause mortality in the East and West 
coasts of Canada and higher rates in the Prairies. These results contradict earlier studies 
suggesting black men may have a biologically distinct form of aggressive prostate cancer 
and highlights the importance of addressing socioeconomic and cultural barriers to 
healthcare.  
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CHAPTER 4:  
Examining the impact of immigration on 
prostate cancer pathology and mortality in 
Canada using the CanCHEC 
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Abstract 
Purpose: Prostate cancer is the second most common cancer diagnosed worldwide, 
however mortality rates vary markedly by country. Men of African and Caribbean 
descent appear to have increased risks of prostate cancer mortality, while men of Asian 
descent have lower risks compared to Caucasian men. It is unclear whether this 
disparity is from a shared genetic factor, from geographic or social practices, or from 
screening and treatment patterns. Immigration studies provide an opportunity to 
examine the impact of genetics and the environment on the risk of prostate cancer 
mortality over time. 
Methods: This study used Statistics Canada’s Canadian Census Health and Environment 
Cohort (CanCHEC) to investigate the impact of ethnicity and immigration on prostate 
cancer mortality. Bivariate analyses were used to predict the association between 
survival time of non-visible minority men (diagnosed 2004-2007) and visible minority 
men (diagnosed 2004-2010) and covariates including immigration and tumor 
characteristics. Sample size concerns necessitated grouping of men of different visible 
minority populations. 
Results: In total 2 335 non-visible minority and 165 visible minority men with prostate 
cancer died of any causes. Of these men 1 095 non-visible minority and 60 non-visible 
minority men died from prostate cancer. Results could not be further stratified by visible 
minority status due to low sample size and missing data. 
Conclusions: While CanCHEC provides access to the variables necessary to determine the 
impact of immigration on prostate cancer mortality over time in Canada, it remains too 
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immature to draw definitive conclusions. Increased follow up times and improved data 
linkages may provide more promising results in the future.  
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Introduction 
Prostate cancer is the second most commonly diagnosed male cancer worldwide with a 
global age-standardized incidence rate of 29 per 100 000 individuals.63 Variable 
mortality rates for prostate cancer are seen globally. The highest rates are seen in 
predominantly African, Latin American and Caribbean nations, while lower rates are 
seen in European, North American and Asian countries.63 Efforts to understand these 
differences have met resistance in controlling for the interplay between potential 
underlying genetic, environmental, and socio-economic factors.  
Immigration studies provide opportunities to examine the impacts of genetics and the 
environment on individuals’ risk for cancer. Comparing cancer characteristics and 
mortality rates between immigrant Canadians and their home country allows one to 
elucidate whether the observed differences may be caused by genetic variants which 
result in more aggressive disease or through socioeconomic factors resulting in poorer 
access to care, screening, or treatment patterns. Should genetic impacts be a 
predominant factor driving mortality rates, no differences should be seen between 
home and host country and the length of time since immigration should not impact 
mortality rates. If the differences are caused by environmental factors – either through 
exposure to a risk factor, screening practices or other socio-economic factors – rates 
should initially mirror the home country before approaching the rate of Canadian men.  
This study uses the Canadian Census Health and Environment Cohort (CanCHEC) to 
investigate the impact of immigration on prostate cancer mortality in Canada. The 
CanCHEC linked long form census data with detailed health, socioeconomic, pathology, 
59 
 
 
 
and survival data. Exploring differences in pathology and mortality data allows for the 
investigation of whether biological or social factors drive the observed ethnic 
differences in prostate cancer survival. Presumably, the observed differences in 
mortality rates are multifactorial; however, the ability to document definitive 
differences between groups provides avenues for further research. 
Methods 
Study design: This retrospective cohort study uses the 1991 CanCHEC data to investigate 
the impact of immigration on the mortality rate among men with prostate cancer in 
Canada. 
Data source: The 1991 CanCHEC is a population-based database which includes linked 
data from the 1991 long-form census, the Canadian Cancer Registry (1992-2010), 
Canadian Vital Statistics Death Database (1921-2016), and historic tax summary files 
(1984-2011), among others.121 Further detailing of the CanCHEC, as well as its linkage 
methodology, is thoroughly described by Peters et al.107  
This study was performed in two phases: the first phase looking at non-visible minority 
Canadian men and the second phase investigating visible minority Canadians. Phase 1 
involves all non-visible minority men involved in the 1991 CanCHEC diagnosed with 
prostate cancer between 2004-2007. These dates were selected to allow access to 
tumor characteristics including TMN staging, grading, and tumor size, which are only 
available during this time period. Phase 2 involved men whom identified as a visible 
minority on the 1991 long-form census. Due to small sample size concerns, Phase 2 was 
expanded to contain diagnoses from 2004-2010 in accordance with Statistics Canada 
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reporting guidelines and the 1985 Statistics Act.122 The CanCHEC allows for longitudinal 
tracking of an individual’s cancer diagnoses and cause of death. A diagnosis of prostate 
cancer was established using the International Classification of Disease coding of C61.  
Statistical methods: Frequency distribution of all-cause and prostate cancer-specific 
mortality was calculated for both Phases, and t tests or chi-squared tests for 
independence were conducted where appropriate. Bivariate analyses were also used to 
predict the association between the survival time of those with prostate cancer and 
covariates. All counts were weighted and rounded to base 5, and percentages were 
based on weighted, rounded counts. Where the weighted frequency of a cell did not 
contain 10 individuals, categories were aggregated where necessary to increase the cell 
count per Statistics Canada guidelines. Hazard ratios, 95% confidence intervals, and p 
values are reported. All analyses were conducted using SAS 9.4 and vetted prior to 
release in accordance with Statistics Canada Research Data Centre protocols. This study 
was approved by the institutional review board of the University of Western Ontario. 
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Results 
In total, 11 580 non-visible minority Canadian men were diagnosed with prostate cancer 
between 2004-2007. 1 095 died from prostate cancer and 2 335 died from any cause.  
 
Died from any cause 
(n=2,335) 
Did not die 
(n=9,245) 
p-value  
Age 
(mean) 
(median) 
63 
64 
51 
51 <.0001 
Education (%)     <.0001 
    No high school 54 33.6   
    Highschool 31.1 36.6   
    Post-secondary non-university 6.6 11.6   
    University 8.4 18.2   
Canadian Region of Diagnosis (%)     0.0002 
    Central Canada 61.4 58.7   
    East Coast 7.5 10.4   
    Prairies 17.1 17.9   
    West Coast 
13.9 
12.8   
    Territories 0.1   
Immigrant Status (%)     0.7677 
    Not an immigrant 79 79.4   
    Immigrant 20.8 20.6   
Tumour Grade (%)     <.0001 
    G1/G2 5.8 14.8   
    G3/G4 13.3 13.8   
    Unreported 80.7 71.4   
T Stage (%)     <.0001 
    T1 2.8 4.9   
    T2 1.9 4.2   
    T3 1.1 
1 
  
    T4 0.4   
    Unreported 93.6 90   
N Stage (%)     <.0001 
    N0 1.7 
3.1 
  
    N1 - N3 0.4   
    Unreported 97.8 97.2   
M Stage (%)     <.0001 
    M0 2.1 
4.6 
  
    M1 1.7   
    Unreported 95.9 95.4   
Tumour Size (%)     <.0001 
    0 - 1.9 cm 0.6 2.4   
62 
 
 
 
    1.9 - 4.9 cm 
0.6 
0.7   
    > 5 cm 0.4   
    Unreported 98.5 96.4   
Table 8 and   
  
Not a Minority 
(n=3,575) 
Minority 
(n=165) 
p-value 3 
Age 
(mean) 
(median) 
61 
63 
58 
58 <.0001 
 
Education (%)     <.0001 
    No high school 52.7 33.3   
    Highschool 31.2 33.3   
    Post-secondary non-university 7.3 12.1   
    University 8.8 21.2   
Canadian Region of Diagnosis 4 (%)     0.0005 
    Central Canada 61.1 72.7   
    West Coast (BC) 14.3 18.2   
    Other 24.8 12.1   
Immigrant Status (%)     <.0001 
    Not an immigrant 79.4 12.1   
    Immigrant 20.6 87.9   
Tumour Grade (%)     0.3669 
    G1/G2 6.3 6.1   
    G3/G4 16.4 12.1   
    Unreported 77.5 78.8   
Table 9 show baseline characteristics of non-visible minority and visible minority men 
diagnosed with prostate cancer in our cohort.  
Parameter Hazard 
Ratio 
95% Hazard 
Ratio 
p-
value 
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Confidence 
Limits 
Age 1.123 1.118 1.128 <.0001 
Education (ref=No high school) 1.036 0.543 1.979 0.9145 
    Highschool 0.59 0.514 0.676 <.0001 
    Post-secondary non-university 0.513 0.409 0.643 <.0001 
    University 0.328 0.261 0.411 <.0001 
Canadian Region of Diagnosis (ref=Central Canada)         
    East Coast 0.769 0.611 0.967 0.0248 
    Prairies 1.006 0.855 1.183 0.9427 
    Territories 0.869 0.157 4.805 0.8718 
    West Coast 1.092 0.914 1.305 0.3317 
Immigrant (ref=not an immigrant) 1.126 0.975 1.302 0.107 
Tumour Grade (ref=unreported)         
    G1/G2 0.147 0.098 0.22 <.0001 
    G3/G4 0.995 0.842 1.175 0.9505 
T Stage (ref=unreported)         
    T1 0.544 0.373 0.793 0.0016 
    T2 0.339 0.202 0.569 <.0001 
    T3 1.923 1.242 2.976 0.0034 
    T4 8.54 4.489 16.244 <.0001 
N Stage (ref=unreported)         
    N0 0.677 0.428 1.071 0.0953 
    N1 - N3 10.762 6.258 18.508 <.0001 
M Stage (ref=unreported)         
    M0 0.503 0.331 0.765 0.0013 
    M1 13.966 10.072 19.364 <.0001 
Tumour Size (ref=unreported)         
    0 - 1.9 cm 0.178 0.069 0.462 0.0004 
    2 - 4.9 cm 0.606 0.24 1.534 0.2907 
    > 5 cm 0.802 0.306 2.101 0.6528 
 Table 10 and  
Parameter Hazard 
Ratio 
95% Hazard Ratio 
Confidence 
Limits 
p-value 
Age 1.105 1.084 1.127 <.0001 
Education (ref=No high school)         
    Highschool 0.753 0.419 1.351 0.3411 
    Post-secondary non-university or university 0.411 0.212 0.799 0.0087 
Canadian Region of Diagnosis (ref=Central Canada)         
    Other 1.218 0.61 2.431 0.576 
    West Coast (BC) 0.998 0.496 2.008 0.9961 
Immigrant (ref=not an immigrant) 0.78 0.366 1.663 0.5201 
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 Table 11 show bivariate analysis of all-cause and prostate cancer-specific mortality. 
Among non-visible minority Canadians, immigration status had no impact on all-cause or 
prostate cancer-specific survival. Increasing age, tumor grade, size, and TNM staging all 
had significant impact on all-cause and prostate cancer-specific mortality. 
Among visible minority men 165 died from any cause and 60 died from prostate cancer.   
  
Not a Minority 
(n=3,575) 
Minority 
(n=165) 
p-value 3 
Age 
(mean) 
(median) 
61 
63 
58 
58 <.0001 
 
Education (%)     <.0001 
    No high school 52.7 33.3   
    Highschool 31.2 33.3   
    Post-secondary non-university 7.3 12.1   
    University 8.8 21.2   
Canadian Region of Diagnosis 4 (%)     0.0005 
    Central Canada 61.1 72.7   
    West Coast (BC) 14.3 18.2   
    Other 24.8 12.1   
Immigrant Status (%)     <.0001 
    Not an immigrant 79.4 12.1   
    Immigrant 20.6 87.9   
Tumour Grade (%)     0.3669 
    G1/G2 6.3 6.1   
    G3/G4 16.4 12.1   
    Unreported 77.5 78.8   
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Table 9 shows baseline characteristics of visible minority men with prostate cancer in our 
cohort. Unfortunately, due to small sample size concerns, significant censoring of the 
data was required. In accordance with Statistics Canada guidelines, the results could not 
be reported by visible minority group. Among visible minority Canadians, immigration 
status did not have a significant impact on all-cause or prostate cancer-specific 
mortality. Visible minority groups had lower rates of both all-cause and prostate cancer-
specific mortality (Figure 8). 
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Died from any cause 
(n=2,335) 
Did not die 
(n=9,245) 
p-value  
Age 
(mean) 
(median) 
63 
64 
51 
51 <.0001 
Education (%)     <.0001 
    No high school 54 33.6   
    Highschool 31.1 36.6   
    Post-secondary non-university 6.6 11.6   
    University 8.4 18.2   
Canadian Region of Diagnosis (%)     0.0002 
    Central Canada 61.4 58.7   
    East Coast 7.5 10.4   
    Prairies 17.1 17.9   
    West Coast 
13.9 
12.8   
    Territories 0.1   
Immigrant Status (%)     0.7677 
    Not an immigrant 79 79.4   
    Immigrant 20.8 20.6   
Tumour Grade (%)     <.0001 
    G1/G2 5.8 14.8   
    G3/G4 13.3 13.8   
    Unreported 80.7 71.4   
T Stage (%)     <.0001 
    T1 2.8 4.9   
    T2 1.9 4.2   
    T3 1.1 
1 
  
    T4 0.4   
    Unreported 93.6 90   
N Stage (%)     <.0001 
    N0 1.7 
3.1 
  
    N1 - N3 0.4   
    Unreported 97.8 97.2   
M Stage (%)     <.0001 
    M0 2.1 
4.6 
  
    M1 1.7   
    Unreported 95.9 95.4   
Tumour Size (%)     <.0001 
    0 - 1.9 cm 0.6 2.4   
    1.9 - 4.9 cm 
0.6 
0.7   
    > 5 cm 0.4   
    Unreported 98.5 96.4   
Table 8. Demographic and clinical data for non-visible minority Canadian men diagnosed with 
prostate cancer between 2004-2007 in the 1991 CanCHEC. 
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Not a Minority 
(n=3,575) 
Minority 
(n=165) 
p-value 3 
Age 
(mean) 
(median) 
61 
63 
58 
58 <.0001 
 
Education (%)     <.0001 
    No high school 52.7 33.3   
    Highschool 31.2 33.3   
    Post-secondary non-university 7.3 12.1   
    University 8.8 21.2   
Canadian Region of Diagnosis 4 (%)     0.0005 
    Central Canada 61.1 72.7   
    West Coast (BC) 14.3 18.2   
    Other 24.8 12.1   
Immigrant Status (%)     <.0001 
    Not an immigrant 79.4 12.1   
    Immigrant 20.6 87.9   
Tumour Grade (%)     0.3669 
    G1/G2 6.3 6.1   
    G3/G4 16.4 12.1   
    Unreported 77.5 78.8   
Table 9. Demographic and clinical data for visible minority Canadian men diagnosed with 
prostate cancer 2004-2010 who died of any cause in the 1991 CanCHEC. 
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Parameter Hazard 
Ratio 
95% Hazard 
Ratio 
Confidence 
Limits 
p-
value 
Age 1.123 1.118 1.128 <.0001 
Education (ref=No high school) 1.036 0.543 1.979 0.9145 
    Highschool 0.59 0.514 0.676 <.0001 
    Post-secondary non-university 0.513 0.409 0.643 <.0001 
    University 0.328 0.261 0.411 <.0001 
Canadian Region of Diagnosis (ref=Central Canada)         
    East Coast 0.769 0.611 0.967 0.0248 
    Prairies 1.006 0.855 1.183 0.9427 
    Territories 0.869 0.157 4.805 0.8718 
    West Coast 1.092 0.914 1.305 0.3317 
Immigrant (ref=not an immigrant) 1.126 0.975 1.302 0.107 
Tumour Grade (ref=unreported)         
    G1/G2 0.147 0.098 0.22 <.0001 
    G3/G4 0.995 0.842 1.175 0.9505 
T Stage (ref=unreported)         
    T1 0.544 0.373 0.793 0.0016 
    T2 0.339 0.202 0.569 <.0001 
    T3 1.923 1.242 2.976 0.0034 
    T4 8.54 4.489 16.244 <.0001 
N Stage (ref=unreported)         
    N0 0.677 0.428 1.071 0.0953 
    N1 - N3 10.762 6.258 18.508 <.0001 
M Stage (ref=unreported)         
    M0 0.503 0.331 0.765 0.0013 
    M1 13.966 10.072 19.364 <.0001 
Tumour Size (ref=unreported)         
    0 - 1.9 cm 0.178 0.069 0.462 0.0004 
    2 - 4.9 cm 0.606 0.24 1.534 0.2907 
    > 5 cm 0.802 0.306 2.101 0.6528 
 Table 10. Bivariate associations for prostate cancer mortality in non-visible minority Canadian 
men diagnosed between 2004-2007 in the 1991 CanCHEC. ref: Reference. 
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Parameter Hazard 
Ratio 
95% Hazard Ratio 
Confidence 
Limits 
p-value 
Age 1.105 1.084 1.127 <.0001 
Education (ref=No high school)         
    Highschool 0.753 0.419 1.351 0.3411 
    Post-secondary non-university or university 0.411 0.212 0.799 0.0087 
Canadian Region of Diagnosis (ref=Central Canada)         
    Other 1.218 0.61 2.431 0.576 
    West Coast (BC) 0.998 0.496 2.008 0.9961 
Immigrant (ref=not an immigrant) 0.78 0.366 1.663 0.5201 
 Table 11. Bivariate associations for prostate cancer mortality among visible minority Canadian 
men diagnosed between 2004-2010 in the 1991 CanCHEC. ref: Reference. HR: Hazard ratio. CI: 
Confidence interval. 
 
 
Figure 8. Survival probabilities for all-cause mortality among visible (diagnosed 2004-2010) and 
non-visible minority (diagnosed 2004-2007) men diagnosed with prostate cancer in the 1991 
CanCHEC. 
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Discussion 
This study was the first to investigate the impact of immigration status on prostate 
cancer-specific mortality using the CanCHEC data. Our findings suggest that although the 
CanCHEC gives access to the variables necessary, the data is too immature for proper 
analysis. The dataset has a maximum follow-up of six years and has 77.5-78.8% of tumor 
characteristics missing in both visible and non-visible minority cohorts. Due to the short 
follow-up and low sample size currently available no meaningful conclusions can 
presently be drawn.  
11 580 non-visible minority Canadians were diagnosed with prostate cancer between 
2004-2007, with 1 095 dying from the disease. With an adequate sample size in this 
cohort we were able to utilize grading and staging information available in the CanCHEC. 
In this population, and in line with the endorsement by the American Joint Committee 
on Cancer, prostate cancer-specific mortality increased with increasing grade and TMN 
stage.26   
In our sample, 881 immigrant Canadians with prostate cancer died with 385 dying from 
prostate cancer. Of the men that died of prostate cancer only 50 were from the visible 
minority cohort. Additionally, nearly 80% of the patients who did die had missing 
pathology data. The high rate of missing pathology data coupled with the low mortality 
rate resulted in significant changes to the initial research question in order to acquire 
data with a sample size large enough to satisfy Statistics Canada guidelines for 
publication. Importantly, this restricted us from publishing analyses capable of 
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stratification by ethnicity and immigration status we believe would be necessary to 
address the primary question of this project. 
Major limitations to this study were small sample sizes, missing data, and a short follow-
up period. Prostate cancer is known to have a long, indolent course. A Swedish study 
which looked at the natural history of prostate cancer over a 21-year period in patients 
with low-grade disease found a substantial increase in prostate cancer-specific mortality 
over time.131 Analysis of 21-year follow-up data found prostate cancer-specific mortality 
nearly tripling – from 15 per 100 000 person-years six years prior, to 44 per 100 000 
person-years.131 Among the immigrant men in the CanCHEC there are over 130 000 
Europeans, 18 000 Chinese and 14 000 South Asians.132 With time, the data from these 
cohorts will continue to mature. We believe that with a longer period of study and 
follow up, coupled with complete pathology data the CanCHEC dataset may be powered 
to assess the impact of immigration on prostate cancer mortality in Canada. 
Our results show no evidence of a healthy immigrant effect in both all-cause and cancer-
specific mortality. This is contradictory to previous studies using both Canadian 
administrative and census data. Ontario-specific hospital administrative data has been 
used to demonstrate a lower all-cause and cancer-specific mortality among immigrants 
as compared to native Canadians diagnosed with one of six index cancers, though data 
was not stratified by cancer type.133 Similarly, the Canadian Census Mortality and Cancer 
Follow-up Study looked at all-cause mortality among Canadian immigrants and found 
lower mortality rates among immigrants compared to Canadians; however, marked 
differences between country of origin were seen.134 The significant censoring, missing 
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data and subsequent small sample sizes currently available likely makes CanCHEC 
underpowered to address these questions. 
With the deficiencies noted above corrected, the CanCHEC data may eventually have 
the ability to further stratify the effect of immigration on mortality by ethnicity and 
cancer type. Ultimately, this could provide insight into underlying genetic, 
environmental, and socio-economic determinants of health in Canada. 
Conclusion 
In conclusion, the current CanCHEC data is too underpowered and immature to assess 
the impact of immigration on prostate cancer mortality in Canada. Nonetheless, it 
remains a unique and powerful dataset with significant potential as it encompasses 
high-level demographic, cancer, and survival data in a first-world, single-payer system. 
Given the long time-course needed to see significant survival differences in prostate 
cancer it is unsurprising that the short follow-up and missing pathology data available 
through the CanCHEC is unable to properly assess the impact of immigration on prostate 
cancer mortality in Canada. Future efforts to expand captured pathologic data, coupled 
with the results from longer follow-up, may improve the power of CanCHEC and identify 
disparities between immigrant and Canadian populations. 
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CHAPTER 5:  
General conclusions and future directions 
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This research project is the first which attempts to use the CanCHEC dataset to 
determine the impact of ethnicity and immigration on prostate cancer mortality in 
Canada. As one of the largest person-based datasets in Canada the CanCHEC reflects 
enough statistical power to reliably detect rare events in small populations. This study 
aims to add longitudinal data, from a diverse population in a single-payer healthcare 
system, to a debate inundated with poor-quality data. 
Our first study on the impact of ethnicity on prostate cancer mortality in Canada 
provided some support as well as some challenges to previously held certainties in 
prostate cancer epidemiology. Our study supports the notion that South and East Asian 
communities may have a biologically distinct form of prostate cancer, resulting in 
improved outcomes. Previous studies which investigated ethnic differences in the 
presentation and outcomes of prostate cancer observed that, while Asian men often 
present with more advanced and higher risk disease, no difference or improved 
outcomes are observed as compared to white men.127,135,136 The largest genetic study, 
which was performed by the International Consortium for Prostate Cancer Genetics, 
used pooled data and statistical modelling to use linkage analysis to identify loci which 
impart increased risk for developing prostate cancer. Unfortunately, less than 2% of the 
data was comprised of Asian families, making application of the identified linkages to 
the Asian population questionable.137 Smaller studies of Asian men have identified other 
potentially provocative and protective loci, however the impact of these loci remains 
unclear.127,138,139 Given the marked heterogeneity and likely polymorphic nature of 
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prostate cancer, separating legitimate protective factors from false signals remains 
exceedingly difficult. 
 Our study also identified no increased risk of prostate cancer mortality among black 
Canadians. Traditionally, black men have been considered a high-risk population for 
prostate cancer with early and aggressive disease seen in black Americans, and high 
rates of prostate cancer mortality seen in predominantly black African and Caribbean 
countries.15,63 Efforts to understand the source for these disparities have suggested 
social, genetic, and environmental factors, though few definitive factors have been 
proven. Similar to Asian men, there is an under-representation of black men in genomic 
studies.140 This has resulted in a poor understanding of any underlying genetic 
mechanisms which result in the observed increased mortality rates. Several studies 
which look at ethnic variations of prostate cancer mutations have found significant 
differences in allelic frequency which correspond with the presumed risk of prostate 
cancer, with Asian men having lowest rates of polymorphisms and African men having 
higher rates compared to Caucasian men.141  
While these patterns were identified, the significance of these genotypic variations and 
how they impact prostate cancer biology remain unknown. Therefore, the conclusions 
that observed mutations in black men result in more aggressive disease assumes that 
black men are in fact at increased risk of aggressive disease. Results from our study 
contradict these assumptions and stress the importance of social determinants of 
health. In a single-payer, universal healthcare system, black men appear to have no 
increased risk of prostate cancer. These results concur with contemporary analysis of 
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American datasets which show no significant differences in prostate cancer mortality 
among black Americans once confounding variables – most importantly socioeconomic 
status and access to healthcare – are controlled.116 
Our study defined ethnicity as the ancestral and cultural roots of an individual, as self-
selected in the 1991 census, leaving the onus on the individual to select (or write in) one 
or more of the provided ethnic groups. Using this definition may further confound the 
issue by grouping individuals from similar, but certainly distinct genetic backgrounds. 
For example, the non-visible minority cohort pools all individuals of minority status 
including those of European, Irish, Scottish, and Scandinavian descent without further 
stratification. Similarly, all Black men are treated as a single entity, despite having 
unique cultures, ethnic practices, and genetic makeup. It is certainly possible that the 
differences seen in our results compared to previously published studies lie in a unique 
Canadian population. Canada has a lower proportion of Caribbean Black men, with just 
over 40% identifying as Caribbean on the 2006 census whereas the American population 
has a more even representation at 53% African and 47% Carribean.93,142 Previous 
genetic analyses have found African American and Caribbean communities carry distinct 
markers as admixed groups – deriving genetic components from both Western African 
and European origins. African American communities show 70-80% African ancestry 
whereas Caribbean communities have higher rates as high as 80-90%.143,144 Both groups 
also contain differing rates of heterogeneity and Asian ancestry. To date no comparable 
study has been performed in the Canadian population. If one is to believe that certain 
groups have a genetic predisposition for certain disease traits, pooling distinct 
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communities into “Black”, “Asian”, and “Other” does researchers a disservice as it 
confounds the data and masks the results. 
CanCHEC has the ability to stratify beyond ethnicity to country of origin. With longer 
follow-up and increasing sample size the potential exists to explore the impact of 
individual sub-regions on prostate cancer mortality. By identifying at risk and protected 
communities one can more closely investigate whether it is underlying genetics, 
environmental, or social factors such as PSA screening rates, driving the observed 
mortality differences.  
A significant limitation to using the CanCHEC to investigate the impact of ethnicity on 
prostate cancer mortality is the inability to identify and to control for family history. 
Given the known propensity for not only an increased incidence, but more aggressive 
familial-linked prostate cancer the inability to control this factor adds in an uncontrolled 
confounding variable.30 An over-representation of non-visible minority individuals with a 
family history or an underrepresentation among visible minority groups may be falsely 
elevating the mortality rate seen in the non-visible minority group or falsely decreasing 
the rate seen in the Black population. 
The 1991 CanCHEC is a powerful and under-utilized tool that can identify disparities in 
mortality rates across geographic, ethnic, and socio-economic groups.107 To date, the 
dataset has been used to investigate a variety of subjects, ranging from the effects of 
profession on cancer risks, to the impacts of pollution, ethnicity, or living near green 
spaces and overall mortality.145,145–151  
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Given the power of the dataset, we investigated the impact of immigration on prostate 
cancer mortality. Unfortunately, significant sample size limitations impaired our ability 
to draw any meaningful conclusions. It is important to note that while our current 
attempt failed, future attempts to address the impact of immigration on cancer 
mortality using the CanCHEC may succeed through increased sample size and longer 
follow-up. The number of individuals captured by each CanCHEC cohort continues to 
climb – from 2.6 million in 1991, to 6.5 million in 2011.152 This increased sample size, in 
conjunction with long-term follow-up, may sufficiently power CanCHEC to draw more 
conclusive results, despite prostate cancer’s long latency period.  
Another significant limitation to investigating the impact of immigration on prostate 
cancer mortality in Canada using the CanCHEC data was the high degree of missing 
pathological data – as high as 79% in our sample. Efforts to reduce this missing data, 
coupled with increased sample size and long-term follow-up, may allow for a more 
definitive evaluation.  
Statistics Canada continues to actively link datasets as new research questions and data 
gaps are identified. Following a needs assessment identifying the value of linking 
treatment data to cancer outcomes, the Canadian Cancer Treatment Linkage Project 
pilot was formed. The goal of the pilot was to investigate the feasibility of linking the 
Canadian Cancer Registry to the Discharge Abstract Database (DAD) and National 
Ambulatory Care Reporting Systems (NACRS). The project was able to successfully link 
over 90% of files, with linkage rates improving with more recent data.153 CanCHEC 
datasets from 2006 onwards have been linked to the DAD, and the 2011 cohort has 
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been linked to the NACRS. Adding treatment data, ideally with pathology data, may 
provide more insight into the observed differences in prostate cancer mortality across 
different groups. 
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CHAPTER 6:  
Conclusions 
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In conclusion, this study was the first to use the CanCHEC to investigate the impacts of 
ethnicity and immigration on prostate cancer mortality in Canada. Our study found that 
Asian ethnicity had a protective effect, while Black men showed no increased rates of 
prostate cancer-specific mortality. In its current form, the CanCHEC is under-powered to 
investigate the impact of immigration; however, this may improve with longer follow-up 
and improved data linkages. This study demonstrates the difficulties and the significant 
risks drawing conclusions from observational data and the power of CanCHEC to 
challenge previously accepted dogma and to investigate rare outcomes on a national 
level.  
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